CoronaVac, BNT162b2 and heterologous COVID-19 vaccine outcomes in patients with ventricular assist device.
COVID-19
vaccine
ventricular assist device
Journal
The International journal of artificial organs
ISSN: 1724-6040
Titre abrégé: Int J Artif Organs
Pays: United States
ID NLM: 7802649
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
pubmed:
11
12
2022
medline:
22
12
2022
entrez:
10
12
2022
Statut:
ppublish
Résumé
A consensus has not yet been reached regarding which COVID-19 vaccine program should be applied in patients with ventricular assist device (VAD). Our aim was to assess the clinical outcome of inactivated, mRNA and heterologous vaccine program in patient with VAD. In this retrospective and cross-sectional study; adult patients who underwent VAD implantation between January 2012 and September 2021 and received any vaccine that were used in Republic of Türkiye for COVID-19, were included. The patients were divided into three groups according to the type of vaccine; "inactivated," "mRNA" and "heterologous." Clinical outcomes were analyzed. Eighteen patients were in each group in the "inactivated," "mRNA" and "heterologous" groups. Mean age was 51.6 ± 12 years in "inactivated" group, 42.5 ± 15.5 years in "mRNA" group and 41.1 ± 15.4 years in "heterologous" group. There was no significant difference between the groups in age, gender, body surface area, body mass index and etiology ( All vaccine that used for COVID-19 are safe and effective in patients with VAD. In countries that give priority to inactivated vaccines, mRNA vaccines may then be made as boosters.
Sections du résumé
BACKGROUND
UNASSIGNED
A consensus has not yet been reached regarding which COVID-19 vaccine program should be applied in patients with ventricular assist device (VAD). Our aim was to assess the clinical outcome of inactivated, mRNA and heterologous vaccine program in patient with VAD.
METHODS
UNASSIGNED
In this retrospective and cross-sectional study; adult patients who underwent VAD implantation between January 2012 and September 2021 and received any vaccine that were used in Republic of Türkiye for COVID-19, were included. The patients were divided into three groups according to the type of vaccine; "inactivated," "mRNA" and "heterologous." Clinical outcomes were analyzed.
RESULTS
UNASSIGNED
Eighteen patients were in each group in the "inactivated," "mRNA" and "heterologous" groups. Mean age was 51.6 ± 12 years in "inactivated" group, 42.5 ± 15.5 years in "mRNA" group and 41.1 ± 15.4 years in "heterologous" group. There was no significant difference between the groups in age, gender, body surface area, body mass index and etiology (
CONCLUSION
UNASSIGNED
All vaccine that used for COVID-19 are safe and effective in patients with VAD. In countries that give priority to inactivated vaccines, mRNA vaccines may then be made as boosters.
Identifiants
pubmed: 36495032
doi: 10.1177/03913988221141719
pmc: PMC9747367
doi:
Substances chimiques
sinovac COVID-19 vaccine
0
COVID-19 Vaccines
0
BNT162 Vaccine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
15-21Références
Nat Med. 2022 Apr;28(4):838-843
pubmed: 35140406
ASAIO J. 2018 May/Jun;64(3):287-294
pubmed: 29095732
J Med Virol. 2022 Apr;94(4):1442-1449
pubmed: 34783049
Circ Heart Fail. 2021 Apr;14(4):e007957
pubmed: 33813838
Ann Thorac Surg. 2008 May;85(5):1656-61
pubmed: 18442560
Lancet Infect Dis. 2022 Jan;22(1):56-63
pubmed: 34509185
JAMA Netw Open. 2022 Mar 1;5(3):e220868
pubmed: 35234883
ESC Heart Fail. 2022 Apr;9(2):905-911
pubmed: 34981657
Eur Heart J Suppl. 2021 Oct 08;23(Suppl E):E184-E188
pubmed: 34650382
Nat Rev Cardiol. 2020 Sep;17(9):543-558
pubmed: 32690910
Lancet Glob Health. 2022 Jun;10(6):e798-e806
pubmed: 35472300
JMIR Public Health Surveill. 2022 May 24;8(5):e35311
pubmed: 35486806
Eur J Med Res. 2021 Aug 25;26(1):98
pubmed: 34433495
Lancet. 2021 Jul 17;398(10296):213-222
pubmed: 34246358
Card Fail Rev. 2015 Apr;1(1):25-30
pubmed: 28785427
JAMA Dermatol. 2021 Aug 1;157(8):1000-1002
pubmed: 34160555
Thromb J. 2021 Nov 13;19(1):86
pubmed: 34774069